CV SciencesMicro-cap bargain stocks are often volatile, and those that are related to cannabis are no exception. CV Sciences Inc. (OTC: CVSI) has seen its share of volatility in recent months, but it remains a compelling option for alternative investors who are looking for something different in the market.

This company is focused on pharmaceuticals, but it has ties to the cannabis market, thanks to its CBD products. With a recent house bill that seeks to legalize cannabis at the federal level, stocks like CV Sciences could be in for a strong upside.

Unlike cannabis producers, CV Sciences already has some protection from legislation. Its hemp-derived CBD products are legal for sale in the United States. The company is currently working on promising drug treatments, including a synthetic CBD variant that could be used to treat tobacco addiction.

Another factor that makes this stock interesting is a recent distribution deal signed with Southeastern Grocers. The deal will see CV Sciences products sold in 37 new stores in South Carolina, and 115 stores in Florida. Expanding the distribution reach could result in stronger revenue performance in the coming quarters.

Stock is down for the year, but that means it is in serious bargain territory. A small investment in this stock could be the perfect addition to a well-diversified alternative portfolio. Analysts currently recommend a BUY rating, with an average target price of $3.80.

Key Data:

  • 1 Year Price Growth: -67.42%
  • YTD Price Growth: -67.98%
  • 3 Month Price Growth: -61.88%

 

All information is based on current and historical market data, as well as publicly available financial data. As with any financial decision, your own research is important. Stock market outcomes can never be 100% accurately predicted. Familiarity with historical data, individual industries, and individual stocks is key to developing a robust portfolio. Note that stock prices can fluctuate rapidly during trading sessions.